ARTICLE | Company News
Priority Review for Lexicon's telotristat etiprate
June 1, 2016 1:19 AM UTC
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) said FDA accepted and granted Priority Review to an NDA for telotristat etiprate ( LX1032) to treat carcinoid syndrome. Its PDUFA date is Nov. 30.
The tryptophan hydroxylase 1 ( TPH1; TPH) inhibitor has Fast Track and Orphan Drug designation in the U.S. Ipsen Group (Euronext:IPN) has exclusive rights to commercialize telotristat etiprate outside the U.S. and Japan. ...